GVS advice on cenobamate (Ontozry®) for the adjunctive treatment of focal-onset seizures
The National Health Care Institute has completed its assessment whether the medicinal product cenobamate (Ontozry®) can be included in the Medicine Reimbursement System (GVS). Cenobamate is indicated for the adjunctive treatment of focal-onset seizures. The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A in the 0N03AXEO V cluster with perampanel and topiramate.
Indication for which reimbursement is requested
Cenobamate is indicated for the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
National Health Care Institute's advice
The National Health Care Institute has concluded that cenobamate meets the established medical science and medical practice as the adjunctive treatment of focal-onset seizures with or without secondary generalisation in adult patients with epilepsy who have not been adequately controlled despite a history of treatment with at least 2 anti-epileptic medicinal products.
The National Health Care Institute recommends the Minister to include cenobamate (Ontozry®) in List 1A in the 0N03AXEO V cluster with perampanel and topiramate.